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In vivo-induced antigen technology is a method to identify proteins
expressed by pathogenic bacteria during human infection. Sera
from 10 patients convalescing from cholera infection in Bangladesh
were pooled, adsorbed against in vitro-grown El Tor Vibrio chol-
erae O1, and used to probe a genomic expression library in
Escherichia coli constructed from El Tor V. cholerae O1 strain
N16961. We identified 38 positive clones in the screen, encoding
pili (PilA and TcpA), cell membrane proteins (PilQ, MshO, MshP, and
CapK), methyl-accepting chemotaxis proteins, chemotaxis and mo-
tility proteins (CheA and CheR), a quorum-sensing protein (LuxP),
and four hypothetical proteins. Analysis of immune responses to
purified PilA and TcpA in individual patients demonstrated that the
majority seroconverted to these proteins, confirming results with
pooled sera. These results suggest that PilA and its outer mem-
brane secretin, PilQ, are expressed during human infection and
may be involved in colonization of the gastrointestinal tract. These
results also demonstrate substantial immune responses to TcpA in
patients infected with El Tor V. cholerae O1. In vivo-induced
antigen technology provides a simple method for identifying
microbial proteins expressed during human infection, but not
during in vitro growth.
V ibrio cholerae is a Gram-negative bacillus that causes asevere, dehydrating diarrhea in humans (1). V. cholerae can
be differentiated by the lipopolysaccharide in the outer mem-
brane; strains of V. cholerae that produce cholera belong to
serogroup O1 or O139. V. cholerae O1 is divided into two
biotypes, classical and El Tor; the current global pandemic of V.
cholerae O1 infection is caused by El Tor strains.
A major virulence factor for pathogenic strains of V. cholerae
is cholera toxin, a protein exotoxin that consists of a single A
subunit noncovalently associated with five B subunits (2). A
second major virulence factor of V. cholerae is the toxin coregu-
lated pilus (TCP; ref. 3). TCP is essential for colonization and
virulence in both mouse models of cholera (3) and human
volunteer studies (4). TcpA, the 20.5-kDa major structural
subunit of TCP, has homology to the type IV pili of several other
bacterial pathogens (5). TcpA from El Tor and classical strains
of V. cholerae show 80% protein homology; monoclonal anti-
bodies demonstrate epitope differences between these proteins
in the two biotypes (6, 7).
In addition to TcpA, the V. cholerae genome encodes two other
type IV pili, the mannose-sensitive hemagglutinin (MSHA) and
PilA (8). MSHA is a thin, flexible pilus composed of a 17-kDa
subunit (9). A strain of V. cholerae deleted in mshA showed no
defect in colonization of human volunteers (10). Recently, Fullner
et al. (11) described a four-gene cluster, pilABCD, encoding a third
type IV pilus in V. cholerae. A deletion of pilA had no effect on
colonization in infant mice. The role of PilA in human infection has
not been previously examined.
Infection with V. cholerae can induce long-lasting protective
immunity against subsequent disease (12, 13), but the full
repertoire of immune responses mediating protection is not
known. The best characterized of the immune responses induced
by V. cholerae is the vibriocidal antibody; elevated vibriocidal
titers correlate with protection from subsequent clinical disease
in seroepidemiologic studies (14–16). Because V. cholerae is a
noninvasive organism, and because there is no disruption of the
intestinal epithelium during cholera, a serum complement-fixing
antibody response such as the vibriocidal antibody may have
minimal activity in the intestinal lumen. The vibriocidal antibody
response, therefore, may be a surrogate marker for an intestinal
response that is the primary mediator of protective immunity.
Immune responses after cholera have also been examined for
a number of other antigens, but none of these responses has been
shown to correlate with protection. Approximately 90% of
individuals in Bangladesh developed an anti-MSHA response in
serum andor stool after cholera (17). The majority of the
anti-cholera toxin (CT) immune response is directed against the
nontoxic B subunit (CtxB). Serum anti-CT and anti-CtxB in-
crease substantially after cholera, but these responses have not
been shown to protect from subsequent disease (16). Intestinal
colonization by V. cholerae is a prerequisite for the development
of immune responses during cholera, and TCP has been shown
to be required for intestinal colonization of human by V. cholerae
(4). However, in volunteer studies in North America, anti-TCP
responses were not found in convalescent sera of individuals
challenged with V. cholerae. Low-level anti-TCP immune re-
sponses were present in convalescent sera from three of six
individuals with cholera in Indonesia (18). It is not clear why
antibody responses to TCP are not more prominent in normal
volunteers, but perhaps immune responses to this pilus require
repeated intestinal exposure. Previous studies of immune re-
sponses to TCP have also been limited by the lack of purified El
Tor TcpA for use in assays; as described above, classical and El
Tor TcpA differ immunologically, and assay of responses after
El Tor cholera by using classical TcpA as antigen may not detect
immune responses appropriately.
All of the antigens described above against which immune
responses have been characterized were identified by using in
vitro-grown V. cholerae. To identify additional microbial antigens
uniquely expressed during infection, a number of newer tech-
niques have been applied to identify gene expression specifically
in vivo, in animal models.
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The first of these techniques, recombinase in vivo expression
technology (RIVET) (19, 20), identified a number of genes in V.
cholerae specifically induced during infection of infant mice,
including a methyl-accepting chemotaxis protein and vieSAB,
encoding a sensor kinase and two distinct response regulatory
proteins (20, 21). RIVET has subsequently been used to study
the spatiotemporal expression of selected V. cholerae genes (tcpA
and ctxAB) during infection in infant mice (22), as well as in a
mutagenesis screen to identify V. cholerae genes required for
expression of ctxAB and toxT in mice (23). This latter screen
identified several chemotaxis genes, a methyl-accepting chemo-
taxis protein, capK (involved in biofilm-associated exopolysac-
charide synthesis), rtxB (encoding the transport gene for the
RTX toxin of El Tor V. cholerae; ref. 24), vieS, mfrha (the
mannosefucose-resistant hemagglutinin), and other genes, as
important regulators of colonization in mice. Signature-tagged
mutagenesis (25) has also been applied to V. cholerae, identifying
a number of genes necessary for colonization and growth in
infant mice, including genes in the TCP cluster, as well as pta,
ptlA, and genes involved in purine biosynthesis (26).
Both RIVET and signature-tagged mutagenesis require an
animal model that mimics human infection. Because humans are
the only known natural hosts for V. cholerae infection, determi-
nation of genes expressed during infection in animal models may
not identify genes uniquely required for human infection.
In vivo-induced antigen technology (IVIAT) is a method that
circumvents limitations of animal models, allowing direct iden-
tification of microbial proteins expressed at sufficient levels
during human infection to be immunogenic (27); these same
proteins may be important for protective immunity after both
natural infection and vaccination. The aim of this study was to
use IVIAT to identify V. cholerae genes specifically expressed
during human infection.
Materials and Methods
Strains, Plasmids, and Media. Strains and plasmids used in this
study are listed in Table 1. Strain N16961 was used to construct
the genomic library described below; the genome sequence of
this strain has been published (8). Bacterial strains were grown
in vitro in LB or AKI media (28), and maintained at 70°C in
LB broth containing 15% glycerol.
Genetic Methods and Strain Construction. Oligonucleotides used for
PCR and DNA sequencing were obtained from Operon Tech-
nologies (Alameda, CA). PCR was performed with TaKaRa Taq
polymerase (New England Biolabs) or Pfx DNA polymerase
(Invitrogen), and an MJ Research (Cambridge, MA) Thermo-
cycler (model PTC 100). PCR templates were prepared by
boiling a single colony of V. cholerae strain N16961 in distilled
H2O, followed by centrifugation and recovery of supernatant.
DNA sequencing was performed at the DNA Sequencing Core
Facility, Department of Molecular Biology, Massachusetts Gen-
eral Hospital. DNA sequences were assembled and ORFs as-
signed with the GENE WORKS ANALYSIS software package (In-
stitute for Genomic Research, Rockville, MD). Plasmids
pLHEAB1, pLHEAB2, pLHEAB3, pLHMA1, and pLH1 for
expressing intact PilQ, PilA, TcpA, TcpF, and MshA from V.
cholerae strain N16961, respectively, were constructed as in
Table 1.
Patient and Control Sera. Serum was collected from patients at the
International Centre for Diarrhoeal Disease Research in Dhaka,
Bangladesh (ICDDR,B); each patient had culture-confirmed
acute diarrheal illness due to El Tor V. cholerae O1, and each
demonstrated a 4-fold or greater rise in vibriocidal antibody titer
between acute and convalescent sera. Patients seen at the
ICDDR,B during the same time period but who were not
infected with V. cholerae (by culture and paired serum vibriocidal
assay) provided control sera. For both groups, sera were ob-
tained on days 0, 9, and 23 after presentation, and stored at
80°C until use. Patients were entered after informed consent,
and the study was approved by the Institutional Review Boards
at both the ICDDR,B and Massachusetts General Hospital.
Adsorption of Sera. We pooled equal volumes of convalescent sera
(both day 9 and day 23) from 10 patients infected with V. cholerae
and extensively adsorbed this pool against an El Tor V. cholerae
strain isolated from one of the patients in the study. Pooled sera
were serially adsorbed against in vitro-grown V. cholerae whole
cells, then French-press extracts, and finally heat-denatured
extracts, as described (27). Resultant adsorbed serum was ali-
quotted and stored at 80°C.
The pool of sera was assayed at various steps of the adsorption
process by using an ELISA reaction against either whole V.
cholerae extracts, or the in vivo-expressed protein CtxB. To assay
antibodies in the serum reactive with whole V. cholerae extracts,
a French-pressed lysate was diluted 1:2 in carbonate buffer (pH
9.6), and 100 l of this lysate was added per well to an ELISA
plate. After blocking and washing, serum samples were added at
dilutions of 1:200 to 1:25,600, and binding was quantitated by
addition of peroxidase-conjugated goat anti-human affinity-
purified Ig (ICN), which is reactive with all classes of human
Table 1. Bacterial strains and plasmids used in this study
Genotype andor phenotype
Reference of
source
Strains
N16961 WT V. cholerae O1 El Tor strain; genomic sequence available: Smr Lab strain
Plasmids
pET30(abc) Expression vectors allowing cloning of fragments in each of three reading frames; Kanr Novagen
pLHEAB1 pET30(a) with intact pilQ gene amplified by PCR from N16961 (1734 bp), and cloned in NdeI and XhoI sites
in vector; Kanr
This work
pLHEAB2 pET30(a) with intact pilA gene amplified by PCR from N16961 (459 bp), and cloned in NdeI and XhoI sites
in vector; Kanr
This work
pLHEAB3 pET30(a) with intact tcpA gene amplified by PCR from N16961 (672 bp), and cloned in NdeI and XhoI sites
in vector; Kanr
This work
pLHMA1 pET30(a) with intact tcpF gene amplified by PCR from N16961 (1014 bp), and cloned in NdeI and XhoI sites
in vector; Kanr
This work
pLH1 pET30(a) with intact mshA gene amplified by PCR from N16961 (534 bp), and cloned in EcoRV and XhoI
sites in vector; Kanr
This work
Smr, streptomycin-resistant; Kanr, kanamycin-resistant; Apr, ampicillin-resistant.
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immunoglobulins. Reactivity was measured by using the sub-
strate 2,2azino-bisethylbenzthiazolinesulfonic acid (Sigma), and
optical density readings at 405 nm were recorded by using a Vmax
microplate reader (Molecular Devices). To assay antibodies
specific for CtxB, wells in an ELISA plate were sequentially
coated with ganglioside (1 g in 110 l of carbonate buffer, pH
9.6) and 100 ng of purified CtxB (List Biological Laboratories,
Campbell, CA). After blocking and washing, pooled sera were
serially diluted from 1:50 to 1:25,600 and added to each well.
Reactivity was measured as above.
Construction of a Genomic Expression Library of V. cholerae O1 Strain
N16961. An expression library was constructed by using pETabc
expression vectors (Novagen); these vectors allow cloning of
inserts in each of three reading frames under transcriptional
control of a T7 promoter. Vector DNA was digested with
BamHI, gel-purified by using the QIAEX II Gel Extraction Kit
(Qiagen, Valencia, CA), and treated with shrimp alkaline phos-
phatase. Genomic DNA from V. cholerae strain N16961 was
partially digested with Sau3A, and two pools of genomic DNA
fragments ranging in size from 0.5–1.5 and 1.0–3.0 kbp were gel
purified. Vector and genomic DNA fragments from each pool
were ligated to create two genomic libraries, and each was
electroporated into competent Escherichia coli DH5 and
spread on LB plates containing kanamycin. After overnight
incubation at 37°C, growth on plates was collected by scraping,
and plasmid DNA was recovered from an aliquot of the library
and electroporated into E. coli BL21 (DE3).
Purification of Proteins. A derivative of TcpA from El Tor V.
cholerae O1, with a histidine tag fused at the amino terminus of
residue 29 of mature TcpA, and a glutathione S-transferase
derivative of TcpF from classical V. cholerae O1, were overex-
pressed and purified as described (29, 30). Purified MshA from
El Tor V. cholerae O1 was purified as described (17). PilA from
N16961 was overexpressed with a carboxyl-terminal hexahisti-
dine tail and purified by using a combination of nickel affinity
chromatography and nondenaturing preparative gel electro-
phoresis (unpublished results).
Screening for Proteins Uniquely Expressed in Vivo by V. cholerae. To
screen the genomic library with adsorbed pooled sera, an aliquot of
the library in expression host BL21 (DE3) was diluted and spread
on LB plates containing kanamycin to produce 300 colonies per
plate. After overnight growth at 37°C, colonies were lifted by using
nitrocellulose membranes, replica plated onto LB plates containing
kanamycin and isopropyl--D-thiogalactoside (1 mM), and incu-
bated overnight at 37°C to induce expression of genes in cloned
inserts. After overnight incubation, plates were exposed to chloro-
form for 15 min to partially lyse bacteria and release induced
proteins, then overlaid with a nitrocellulose membrane for 15 min
at room temperature. Each membrane was removed, blocked with
10% nonfat skim milk, and reacted with a 1:100 dilution of adsorbed
pooled sera at room temperature for 1 h with mild agitation. Clones
reacting with antibody in adsorbed sera were detected by using
peroxidase-conjugated goat, anti-human Ig at a 1:5,000 dilution,
and developed by using an ECL chemiluminescence kit (Amersham
Pharmacia Biotech). Reactive clones were identified by their po-
sition on the master plate; each positive clone was purified at least
two additional times and confirmed as reactive with adsorbed sera.
Plasmids from individual reactive clones were purified, and the V.
cholerae DNA inserted in the vector was sequenced in both
directions by using pET30-specific primers (Novagen). PCR with
these same primers was used to estimate the size of inserted DNA.
Altogether, 30,000 clones from the two differently sized DNA
expression libraries were screened, and 38 positive clones were
identified, confirmed on multiple occasions, and sequenced. Pro-
teins encoded in the cloned insert fragments were identified by
using the genomic sequence of V. cholerae strain N16961.
To further confirm specific recognition of PilA, PilQ, TcpA,
TcpF, and MshA by pooled, adsorbed convalescent sera from
cholera patients, we used expression plasmids for each intact
protein in a dot-blot hybridization assay identical to the IVIAT
screen of the library above, to confirm immunoreactivity. As a
control, results were compared with those with empty plasmid
vector.
Analysis of RNA Transcription of Selected Genes in Vitro by RT-PCR.
After overnight culture of strain N16961 in LB broth or AKI
media, RNA was isolated by using TRIzol (Invitrogen) accord-
ing to the manufacturer’s instructions. RNA was purified with an
RNeasy Mini Kit (Qiagen) and treated with an RNase-Free
DNase kit (Qiagen) according to the manufacturer’s instruc-
tions. RNA was eluted in diethyl pyrocarbonate-treated water
and treated with DNase I (Ambion, Austin, TX). Control PCRs
were performed on the purified RNA preparations to ensure
absence of amplification from contaminating DNA. Reverse
transcription to cDNA was done by using a Reverse Transcrip-
tion System (Promega). Primers specific for tcpA, pilA, pilQ, and
rpoB (as a control) were used in PCRs on cDNA; primers were
obtained from the Tufts University Core Facility (Boston). PCR
products were detected on a 1.5% agarose gel with ethidium
bromide.
Results and Discussion
Adsorption of a Pool of Sera from Patients Convalescing from Cholera
Removes Antibodies Against Most V. cholerae Proteins Expressed in
Vitro but Not Those Expressed in Vivo. Pooled sera from patients
convalescing from cholera in Bangladesh were successively ad-
sorbed against in vitro grown V. cholerae. As shown in Fig. 1A,
there was a progressive decrease in reactivity of the pooled sera
with in vitro-grown V. cholerae, particularly after the French
press lysate adsorption step. In contrast, there was substantially
less removal of antibodies recognizing CtxB (Fig. 1B). Cholera
toxin is not significantly expressed by El Tor V. cholerae during
growth in LB broth, but is expressed during human infection.
Retention of immunoreactivity to in vivo-expressed V. cholerae
proteins in pooled convalescent sera after adsorption was further
assessed by using individual purified proteins. In addition to
CtxB, we included purified MshA and TcpF, a protein in the TCP
gene cluster that is secreted by V. cholerae (30). Genes in the TCP
cluster in El Tor V. cholerae are not expressed during growth in
LB broth but are expressed during human infection. As shown
in Fig. 2A, substantial reactivity to in vivo-expressed V. cholerae
proteins was retained after adsorption of convalescent sera.
Use of Adsorbed Convalescent Sera to Probe a Genomic DNA Expres-
sion Library of V. cholerae Strain N16961. Screening of the two
expression libraries with the adsorbed convalescent sera yielded
38 clones that were persistently reactive after at least three
rounds of purification. The identity of proteins encoded by
clones reactive with convalescent sera is shown in Table 2; these
reactive clones include proteins encoding two of the type IV pili
in V. cholerae (PilA and TcpA), a minor component of the
MSHA pilus (MshO) and a related outer membrane protein
(MshP), a cell membrane protein (PilQ) that acts as an outer
membrane secretin for PilA in other organisms, a cell membrane
protein (CapK) that is involved in biofilm-associated exopolysac-
charide synthesis, three methyl-accepting chemotaxis proteins,
two proteins involved in chemotaxis and motility (CheA and
CheR), a quorum-sensing protein (LuxP), and four hypothetical
ORFs. Most of the reactive clones contained only a portion of
the coding sequence of the relevant protein product. A number
of reactive clones expressed V. cholerae proteins previously
detected by screens in infant mice by using RIVET and signa-
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ture-tagged mutagenesis, including TcpA (which was identified
eight times in the screen), three different methyl-accepting
chemotaxis proteins, and CapK.
IVIAT also identified several clones containing genes not
detected in previous screens in infant mice, including mshO,
mshP, cheA, cheR, luxP, and four hypothetical ORFs. LuxP is a
periplasmic protein that is a component of one of three recently
described quorum-sensing systems in V. cholerae (31). Of the
four hypothetical ORFs identified, three (VCA0536, VCA0884,
and VCA0931) are predicted to encode cytoplasmic membrane
proteins (PSORT program), and one (VC1431) has a signal
peptide (SIGNALP program; www.cbs.dtu.dkservicesSignalP-
2.0) and a motif homologous to a bacterial chemotaxis sensory
transducer (MOTIF program); PSORT and MOTIF analyses were
done with tools available at free web-based resources such as the
Baylor College of Medicine (http:searchlauncher.bam.
tmc.edu). Interestingly, three of the four hypothetical ORFs
identified are encoded on the smaller chromosome II of V.
cholerae (32). Chromosome II has many fewer genes required for
growth of V. cholerae in laboratory media, but contains many
genes necessary for adaptation and growth of V. cholerae in
unique environments (8). The fact that three of four hypothetical
ORFs identified by IVIAT are encoded on chromosome II raises
the possibility that these genes may encode functions specifically
required for growth in human intestine.
The V. cholerae gene sequence identified most frequently by
IVIAT was that encoding PilA, the structural subunit of a third
type IV pilus in V. cholerae (identified 17 separate times in the
IVIAT screen). In addition, IVIAT identified antibody in con-
valescent sera to PilQ. Sera from control patients did not
recognize clones encoding PilA or PilQ. The fact that PilA and
PilQ are expressed and immunogenic during human infection,
but that mutation of pilA has no effect on colonization of infant
mice by V. cholerae, raises the possibility that PilA and its
assembly apparatus may play a specific role in colonization of
human intestine.
To confirm the results of the IVIAT screen, we constructed
plasmids specifically expressing TcpA, TcpF, MshA, PilA, and PilQ
and examined reactivity of adsorbed patient sera with E. coli
containing each of these plasmids. As shown in Fig. 2B, each
selected clone showed prominent reactivity with adsorbed conva-
lescent sera whereas a strain containing the control plasmid did not.
Individual Patients with El Tor V. cholerae Infection Develop Specific
Immune Responses to Purified TcpA and PilA After Infection. Because
of the importance of type IV pili in colonization of the gastroin-
testinal tract, and because adsorbed, convalescent sera from pa-
tients specifically recognized all three V. cholerae type IV pili, we
focused on further analysis of immune responses to these pili. We
examined whether TcpA and PilA reactivity was present at high
level in a subset of patients from whom sera was pooled, or if most
or all of individual patients recovering from cholera had antibody
reactive to these proteins. For this purpose, we used immunoscreen-
ing with purified TcpA and PilA (see Materials and Methods) and
unadsorbed sera from days 0, 9, and 23 after V. cholerae infection,
comparing results to control patients who did not have V. cholerae
infection; because the quantities of purified TcpA and PilA were
limited, we used a dot-blot assay for analysis. Results in Fig. 3 show
that, between day 0 and day 23, 6 patients increased immunoreac-
tivity to PilA and 4 patients (numbers 2, 8, 9, and 10) showed
immunoreactivity that did not change or decreased, suggesting that
infection with V. cholerae may have begun earlier than study entry.
For TcpA, 6 of 10 patients showed increasing reactivity, 3 patients
(numbers 8, 9, and 10) showed immunoreactivity that did not
change (or decreased) and 1 patient (patient 7) did not show
immunoreactivity to TcpA, despite having culture-documented
El Tor V. cholerae O1 infection and antibody to PilA. Control
patients did not demonstrate significant immunoreactivity with
either protein.
Fig. 1. ELISA results after sequential steps in adsorption of pooled, patient sera; OD values are corrected for background and for dilution during adsorption
steps. (A) Shown are ELISA plates coated with whole V. cholerae extracts. (B) Shown are ELISA plates coated with GM1 ganglioside and CtxB. FP, French press.
Fig. 2. Results using pooled, convalescent sera after complete adsorption.
(A) Individual, purified proteins were spotted on a nitrocellulose membrane
and the membrane developed by using pooled convalescent sera. (B) Individ-
ual E. coli BL21 strains containing plasmids expressing specific proteins (or
control plasmid, pET30a) were transferred to a nitrocellulose membrane and
developed by using pooled patient sera after adsorption.
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Type IV pili share homology at the amino terminus (5). We
considered the possibility that the serologic responses might
be directed to epitopes shared between TcpA and PilA. How-
ever, the histidine-tagged form of TcpA used in our assay is
missing the first 28 aa of the mature protein, the area of
highest homology between type IV pili. Therefore, it is unlikely
that the results represent crossreactivity between these two
different pilus proteins. In addition, IVIAT identified reactivity
with other components of each of the type IV pilus systems of
V. cholerae, and these components do not share the same
homology as the mature pilus subunits. These findings document
strong human immune responses to TcpA and PilA after El Tor
V. cholerae O1 infection.
Assessment of Expression of Selected Genes in Vitro by RT-PCR. We
assessed expression of selected genes in vitro by using RT-PCR
(data not shown). Transcription of tcpA was not detected after
growth in LB broth but was present after growth in AKI media,
Fig. 3. Comparison of reactivity of unadsorbed sera from individual patients collected on days 0, 9, and 23 after V. cholerae infection, and control patients from
day 23, against purified El Tor PilA or TcpA.
Table 2. V. cholerae proteins encoded in clones identified by IVIAT
Functional classes of
encoded protein products
Name of encoded
protein product
Gene designation
in V. cholerae
genome sequence
Encoded on
chromosome I or II
No. of clones
identified in IVIAT screen
Pili PilA VC2423 I 17
TcpA VC0828 I 8
Cell membrane proteins PilQ VC2630 I 1
MshO* VC0412 I 1
MshP* VC0413 I
CapK VC0924 I 1
Methyl-accepting MCP VCA0176 II 1
chemotaxis proteins MCP VCA1056 II 1
MCP VC0216 I 1
Chemotaxis and motility CheA VC1397 I 1
proteins CheR VC1399 I 1
Quorum-sensing protein LuxP VCA0737 II 1
Hypothetical proteins VCA0536 II 1
VCA0884 II 1
VCA0931 II 1
VC1431 I 1
*These two genes were encoded on the same recovered fragment.
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as previously reported (22). Expression of pilA was detected after
overnight growth in both LB broth and AKI media, even though
antibodies reactive with PilA were not removed during the
adsorption process. Expression of pilQ could not be detected
after growth in either media. The control gene, rpoB, was
expressed in both media as expected.
Because the RT-PCR results suggested no transcription of
pilQ in LB broth, one possibility is that pilA is transcribed, but
PilA is not assembled on the cell surface because of the absence
of PilQ (and perhaps other components of the assembly ma-
chinery). This result might lead to premature degradation of
PilA when V. cholerae is grown in LB broth.
Xu et al. (33) analyzed genes specifically expressed by El Tor
V. cholerae during growth in a rabbit ileal loop, by using a gene
microarray. They demonstrated that genes for mshABCD are
highly expressed in rabbit ileal loop compared with in vitro, as are
genes for motility and chemotaxis. Merrell et al. (34) demon-
strated that V. cholerae recovered directly from human stool are
hyperinfectious for infant mice compared with organisms grown
in LB broth. Transcriptional profiling of V. cholerae in human
stool suggested induction of genes involved in nutrient acquisi-
tion and motility, perhaps correlating with enhanced infectivity
to subsequent hosts. Bina et al. (35) examined gene expression
in V. cholerae in stools rapidly frozen at the bedside of cholera
patients . Their results showed that several genes involved in
pathogenesis were more highly expressed in stool compared with
growth in LB broth; these more highly expressed genes included
ctxAB, mshK, mshO, mshP, pilE, the pilOPQ operon, and cheA;
of these genes, cheA and the pilOPQ operon were particularly
strongly expressed during human infection. The genes for tcpA
and mshA were less strongly expressed.
IVIAT identified many of the genes that were strongly ex-
pressed in both rabbit ileal loops and human stool, particularly
genes encoding cell surface proteins (such as PilQ, MshO, MshP,
CapK, the methyl-accepting chemotaxis proteins, and the hypo-
thetical ORFs), or cytoplasmic proteins that are particularly
strongly expressed in human stool, such as CheA. However,
IVIAT did not identify all genes strongly expressed in human
stool, particularly those whose protein products are not surface
localized. This result may in part be due to the fact that our
screen of the V. cholerae genome is not saturated, as demon-
strated by the fact that we did not yet identify clones for cholera
toxin, despite the fact that its in vivo expression is well estab-
lished. It is also of interest that all of the genes from chromosome
II of V. cholerae identified as expressed during human infection
by IVIAT were expressed poorly in human stool by using
microarray technology (35). One possibility is that genes on
chromosome II turn off expression particularly quickly during
the transit from the upper gastrointestinal tract to stool. IVIAT
seems to preferentially identify proteins that are surface local-
ized and highly immunogenic during human infection with a
mucosal pathogen such as V. cholerae. Because these same
proteins are likely involved in generating protective immune
responses, IVIAT may provide data that enhance microarray
technology to identify relevant antigens expressed in vivo.
The fact that convalescent sera from cholera patients specif-
ically recognizes PilA and PilQ suggests that this pilus may be
uniquely expressed during human infection, and may play a role
in V. cholerae pathogenesis not suspected by previous animal
model experiments. IVIAT may provide a new technology to
detect genes specifically expressed during human infection. An
important next step will be to use IVIAT in a more complete
screen of the V. cholerae genome.
We appreciate the thoughtful comments of Drs. John J. Mekalanos, David
Sack, and Firdausi Qadri. Dr. Ann-Mari Svennerholm provided MshA for
the study, and Drs. A. S. G. Faruque, M. A. Salam, and G. J. Fuchs were
involved in a study in which sera used here were collected. This work was
supported by Grants UO1 HD39165 (to S.B.C.), RO1 AI44487 (to S.B.C.),
RO1 AI25096 (to R.K.T.), RO1 AI40725 (to E.T.R.), and RO1 DE13523
(to M.H.) from the National Institutes of Health and Grant D43 TW05572
(to S.B.C.) from the Fogarty International Center.
1. Kaper, J. B., Morris, J. G. J. & Levine, M. M. (1995) Clin. Microbiol. Rev. 8,
48–86.
2. Gill, D. M. (1976) Biochemistry 15, 1242–1248.
3. Taylor, R. K., Miller, V. L., Furlong, D. B. & Mekalanos, J. J. (1987) Proc. Natl.
Acad. Sci. USA 84, 2833–2837.
4. Herrington, D. A., Hall, R. H., Losonsky, G., Mekalanos, J. J., Taylor, R. K.
& Levine, M. M. (1988) J. Exp. Med. 168, 1487–1492.
5. Patel, P., Marris, C. F., Mattick, J. S., Ruehl, W. W., Taylor, R. K. & Koomey,
M. (1991) Infect. Immun. 59, 4674–4676.
6. Sun, D. X., Mekalanos, J. J. & Taylor, R. K. (1990) J. Infect. Dis. 161, 1231–1236.
7. Rhine, J. A. & Taylor, R. K. (1994) Mol. Microbiol. 13, 1013–1020.
8. Heidelberg, J. F., Eisen, J. A., Nelson, W. C., Clayton, R. A., Gwinn, M. L.,
Dodson, R. J., Haft, D. H., Hickey, E. K., Peterson, J. D., Umayam, L., et al.
(2000) Nature 406, 477–483.
9. Jonson, G., Holmgren, J. & Svennerholm, A. M. (1991) Microb. Pathog. 11,
433–441.
10. Tacket, C. O., Taylor, R. K., Losonsky, G., Lim, Y., Nataro, J. P., Kaper, J. B.
& Levine, M. M. (1998) Infect. Immun. 66, 692–695.
11. Fullner, K. J. & Mekalanos, J. J. (1999) Infect. Immun. 67, 1393–1404.
12. Cash, R. A., Music, S. I., Libonati, J. P., Snyder, M. J., Wenzel, R. P. & Hornick,
R. B. (1974) J. Infect. Dis. 129, 45–52.
13. Cash, R. A., Music, S. I., Libonati, J. P., Craig, J. P., Pierce, N. F. & Hornick,
R. B. (1974) J. Infect. Dis. 130, 325–333.
14. Mosley, W. H., Benenson, A. S. & Barui, R. (1968) Bull. W. H. O. 38, 327–334.
15. Glass, R. I., Becker, S., Huq, M. I., Stoll, B. J., Khan, M. U., Merson, M. H.,
Lee, J. V. & Black, R. E. (1982) Am. J. Epidemiol. 116, 959–970.
16. Glass, R. I., Svennerholm, A. M., Khan, M. R., Huda, S., Huq, M. I. &
Holmgren, J. (1985) J. Infect. Dis. 151, 236–242.
17. Qadri, F., Jonson, G., Begum, Y. A., Wenneras, C., Albert, M. J., Salam, M. A.
& Svennerholm, A. M. (1997) Clin. Diagn. Lab. Immunol. 4, 429–434.
18. Hall, R. H., Losonsky, G., Silveira, A. P., Taylor, R. K., Mekalanos, J. J.,
Witham, N. D. & Levine, M. M.. (1991) Infect. Immun. 59, 2508–2512.
19. Camilli, A., Beattie, D. T. & Mekalanos, J. J. (1994) Proc. Natl. Acad. Sci. USA
91, 2634–2638.
20. Camilli, A. & Mekalanos, J. J. (1995) Mol. Microbiol. 18, 671–683.
21. Lee, S. J., Angelichio, M. J., Mekalanos, J. J. & Camilli, A. (1998) J. Bacteriol.
180, 2298–2305.
22. Lee, S. H., Hava, D. L., Waldor, M. K. & Camilli, A. (1999) Cell 99, 625–634.
23. Lee, S. H., Butler, S. M. & Camilli, A. (2001) Proc. Natl. Acad. Sci. USA 98,
6889–6894.
24. Lin, W., Fullner, K. J., Clayton, R., Sexton, J. A., Rogers, M. B., Calia, K. E.,
Calderwood, S. B., Fraser, C. & Mekalanos, J. J. (1999) Proc. Natl. Acad. Sci.
USA 96, 1071–1076.
25. Hensel, M., Shea, J. E., Gleeson, C., Jones, M. D., Dalton, E. & Holden, D. W.
(1995) Science 269, 400–403.
26. Chiang, S. L. & Mekalanos, J. J. (1998) Mol. Microbiol. 27, 797–805.
27. Handfield, M., Brady, L. J., Progulske-Fox, A. & Hillman, J. D. (2000) Trends
Microbiol. 8, 336–339.
28. Murley, Y. M., Behari, J., Griffin, R. & Calderwood, S. B. (2000) Infect. Immun.
68, 3010–3014.
29. Craig, L., Taylor, R. K., Pique, M. E., Adair, B. D., Arvai, A. S., Singh, M.,
Lloyd, S. J., Shin, D. S., Getzoff, E. D., Yeager, M., et al. (2003) Mol. Cell 11,
1139–1150.
30. Kirn, T. J. & Taylor, R. K. (2003) Mol. Microbiol., in press.
31. Miller, M. B., Skorupski, K., Lenz, D. H., Taylor, R. K. & Bassler, B. L. (2002)
Cell 110, 303–314.
32. Trucksis, M., Michalski, J., Deng, Y. K. & Kaper, J. B. (1998) Proc. Natl. Acad.
Sci. USA 95, 14464–14469.
33. Xu, Q., Dziejman, M. & Mekalanos, J. J. (2003) Proc. Natl. Acad. Sci. USA 100,
1286–1291.
34. Merrell, D. S., Butler, S. M., Qadri, F., Dolganov, N. A., Alam, A., Cohen, M. B.,
Calderwood, S. B., Schoolnik, G. K. & Camilli, A. (2002) Nature 417, 642–644.
35. Bina, J., Zhu, J., Dziejman, M., Faruque, S., Calderwood, S. & Mekalanos, J.
(2003) Proc. Natl. Acad. Sci. USA 100, 2801–2806.
Hang et al. PNAS  July 8, 2003  vol. 100  no. 14  8513
M
IC
RO
BI
O
LO
G
Y
